Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by chipmuki1234567on Mar 05, 2018 11:40pm

115 Views

Post# 27665509

RE:RE:RE:Dr wallace - Resume summary

Nicox said today it agreed to acquire Aciex Therapeutics for up to $120 million, in a deal that the buyer said would help it advance its strategy of building a global company focused on eye therapeutics and diagnostics, with U.S. and European commercial operations.

https://www.genengnews.com/gen-news-highlights/nicox-buys-aciex-for-up-to-120m/81250058/

Bullboard Posts

Walmart stock and revenue both on the rise